Cemindia Projects Ltd sees a credit rating action
TL;DR
What specific financial metrics—such as interest coverage ratio, debt-to-equity, or working capital cycle—did CARE Ratings cite as the primary drivers for this upgrade compared to the previous rating cycle?
CARE Ratings did not cite any specific interest-coverage, debt-to-equity, or working-capital-cycle figures in the 3 September 2026 exchange disclosure. The filing reports only the rating actions: long-term facilities were upgraded from CARE A+; Stable to CARE AA-; Stable, while commercial paper moved from CARE A1 to CARE A1+ [1].
Accordingly, the disclosure does not establish:
- the current or prior-cycle interest coverage ratio;
- the current or prior-cycle debt-to-equity ratio;
- working-capital days or any improvement in the working-capital cycle;
- quantified changes in debt, finance costs, liquidity, or cash-flow coverage.
The notification confirms that CARE communicated revised ratings to Cemindia Projects, but it does not reproduce the rating rationale or the financial-metric comparison behind the upgrade [1]. Therefore, the primary drivers cannot be identified from this filing without the underlying CARE rationale report; attributing the upgrade to leverage, coverage, or working-capital improvement would be inference rather than a cited CARE conclusion.
Given the upgrade, what is the current quantum of the company's rated debt facilities (fund-based vs. non-fund-based), and how does the management expect this to translate into a reduction in finance costs or improved bank guarantee margins?
The rating notification does not disclose the rupee quantum of the rated facilities. It identifies the instruments and their revised ratings, but provides neither sanctioned limits nor outstanding amounts; therefore, the current fund-based versus non-fund-based split cannot be quantified from this disclosure.
Finance-cost and bank-guarantee impact: no management estimate is provided for either:
- reduction in interest expense or borrowing spreads;
- lower bank-guarantee commission or margin requirements;
- release of collateral or cash margin; or
- the timing of any repricing.
The upgrade is from CARE A+ to CARE AA- for the long-term facilities and from CARE A1 to CARE A1+ for the short-term and BG/LC components [1]. Analytically, this should improve the company’s negotiating position with lenders and could support lower borrowing spreads or BG margins, but the magnitude remains unquantified and should not yet be treated as a forecast saving. The notification is a credit-rating update, not a financing-cost guidance statement.
| Category | Rated facilities | Revised rating | Current quantum |
|---|---|---|---|
| Fund-based heading | Term loan, cash credit, vendor financing | CARE AA-; Stable | Not disclosed [1] |
| Short-term instrument | Commercial paper | CARE A1+ | Not disclosed [1] |
| Non-fund-based | Bank guarantee / letter of credit facilities | CARE AA-; Stable / CARE A1+ | Not disclosed [1] |
How does the company's current debt-to-equity ratio and liquidity position, as highlighted in the rating rationale, compare to its historical performance over the last three fiscal years, and does this upgrade reflect a structural improvement in cash flow generation?
Verdict: The balance sheet is stronger than in FY25, but the improvement has largely stabilised rather than continued. Consolidated debt-to-equity declined from 0.51x in FY25 to 0.36x in FY26 and remained 0.36x in Q1 FY27; the current ratio improved from 1.14x to 1.25x and has also remained at 1.25x. The upgrade is therefore supported by lower leverage and better liquidity, but the available evidence is not sufficient to call it a fully structural improvement in cash-flow generation.
Cash-flow quality: FY26 was clearly better: operating cash flow increased from Rs 202.70 Crores to Rs 499.78 Crores, while OCF-to-revenue improved from 2.2% to 5.0% [7] [8]. Cash and equivalents also rose 32.7% year on year to Rs 474.69 Crores [9] [6]. Debtors turnover improved from 6.46x in FY25 to 6.90x in FY26 and 7.02x in Q1 FY27, which is directionally supportive of collections [10].
However, the evidence remains mixed on durability. Financing cash flow stayed negative and became more negative in FY26 at minus Rs 242.52 Crores versus minus Rs 208.84 Crores in FY25, while investing cash outflow remained negative at minus Rs 148.99 Crores [11] [12]. Further, Q1 FY27 net debt-to-EBITDA was 1.38x, versus 0.33x in FY26, even though the debt-to-equity ratio was unchanged [13]. That divergence suggests that the current quarter’s earnings base or cash-flow conversion needs monitoring; the improvement is not uniform across every leverage measure.
The 3 September 2026 exchange filing records CARE’s upgrade of long-term facilities to CARE AA-; Stable from CARE A+; Stable, and commercial paper to CARE A1+ from CARE A1 [1]. The filing records the rating action but does not provide the detailed rating-rationale bridge. On the reported numbers, the upgrade is consistent with FY26 deleveraging, stronger interest coverage—from 3.20x in FY25 to 4.77x in FY26 and 5.70x in Q1 FY27—and improved liquidity [14]. But a structural cash-flow conclusion would require sustained OCF generation and cash retention beyond FY26; Q1 FY27 OCF and cash balances are not reported in the cited KPI series. A strict three-full-year comparison is also unavailable because FY24 is not reported in that series.
| Consolidated metric | FY25 | FY26 | Q1 FY27 | Analyst read |
|---|---|---|---|---|
| Debt-to-equity | 0.51x [2] | 0.36x [2] | 0.36x [2] | Deleveraging followed by stability |
| Net debt-to-equity | 0.31x [3] | 0.16x [3] | 0.16x [3] | Net leverage more than halved versus FY25 |
| Current ratio | 1.14x [4] | 1.25x [4] | 1.25x [4] | Liquidity improved and then plateaued |
| Net debt | Rs 575.16 Crores [5] | Rs 392.11 Crores [5] | Rs 392.11 Crores [5] | Lower debt after FY25 |
| Cash and equivalents | Rs 357.67 Crores [6] | Rs 474.69 Crores [6] | Not reported for Q1 FY27 | FY26 cash buffer improved |
| Operating cash flow | Rs 202.70 Crores [7] | Rs 499.78 Crores [7] | Not reported for Q1 FY27 | Strong FY26 improvement, but limited repeat evidence |
Sources
- [1]Cemindia Projects Ltd: CARE Ratings Upgrades Credit Ratings for Various Facilities — 2026-09-03T19:58:41, p.1
- [2]Debt Equity Ratio
- [3]Net Debt to Equity
- [4]Current Ratio
- [5]Net Debt
- [6]Cash and Equivalents
- [7]TTM Operating Cash Flow
- [8]TTM OCF to Revenue
- [9]Cash and Equivalents YoY
- [10]Debtors Turnover
- [11]TTM Cash Flow from Financing
- [12]TTM Cash Flow from Investing
- [13]Net Debt to EBITDA
- [14]Interest Coverage Ratio
Keep digging